Literature DB >> 23971448

MRCP in patient care: a prospective survey of gastroenterologists.

M Fatih Akisik1, S Gregory Jennings, Alex M Aisen, Stuart Sherman, Gregory A Cote, Kumaresan Sandrasegaran, Temel Tirkes.   

Abstract

OBJECTIVE: MRCP is increasingly used to evaluate pancreaticobiliary disease, yet its effect on patient care is unknown. The purpose of this study was to measure the effect of MRCP on referring physicians' initial diagnoses, the physicians' confidence in their diagnoses, and the influence of MRCP results on clinical management. SUBJECTS AND METHODS: We prospectively surveyed gastroenterologists who referred patients for nonurgent MRCP for pancreaticobiliary evaluation. Before MRCP, gastroenterologists reported the working diagnosis, confidence level (high, moderate, low), and next step in clinical management if MRCP was unavailable. MRCP was performed with standard protocols, including secretin enhancement. After reviewing MRCP findings and without referring to their previous assessment, gastroenterologists reported a revised diagnosis, confidence level, and next step in clinical management. They then compared pre- and post-MRCP management plans and rated the influence of MRCP on changing management from 1 (none) to 5 (major). Diagnostic confidence and frequency of common diagnoses and recommendation for an invasive next-step procedure (e.g., ERCP) or endoscopic ultrasound were compared between pre- and post-MRCP assessments.
RESULTS: Survey data were analyzed on 171 patients (123 women, 48 men; mean age, 50 [SD, 17] years; range, 19-88 years) undergoing MRCP for unexplained abdominal pain (42.9%), suspected pancreaticobiliary neoplasm (20%), recent acute (17.1%) or suspected chronic (14.9%) pancreatitis, and other indications (5.1%). Recommendations of ERCP and endoscopic ultrasound decreased after MRCP (from 49.1% to 35.1%, p=0.03, and from 26.9% to 13.5%, p≤0.01). After MRCP, high confidence in diagnosis increased (from 72/171 to 100/171, p<0.01), as did recommendations for noninvasive therapy (from 18/171 to 56/171, p<0.01). A major or substantial change in clinical management was made in the care of 67 of 171 patients (39.2%).
CONCLUSION: Use of MRCP significantly changes gastroenterologists' treatment of patients with suspected pancreaticobiliary disease by increasing diagnostic confidence and reducing the frequency of invasive follow-up procedures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23971448     DOI: 10.2214/AJR.12.9900

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

Review 1.  Chronic Pancreatitis: What the Clinician Wants to Know from MR Imaging.

Authors:  Temel Tirkes
Journal:  Magn Reson Imaging Clin N Am       Date:  2018-08       Impact factor: 2.266

2.  Utilization trends in inpatient endoscopic retrograde cholangiopancreatography (ERCP): A cross-sectional US experience.

Authors:  Moiz Ahmed; Ritesh Kanotra; Ghanshyambhai T Savani; Fenilkumar Kotadiya; Nileshkumar Patel; Sarah Tareen; Matthew J Fasullo; Mayurathan Kesavan; Ahsan Kahn; Nikhil Nalluri; Hafiz M Khan; Dhaval Pau; Jeffrey Abergel; Liliane Deeb; Sherif Andrawes; Ananya Das
Journal:  Endosc Int Open       Date:  2017-04

3.  The Role of Laparoscopic Ultrasonography in the Evaluation of Suspected Choledocholithiasis. A Single-Center Experience.

Authors:  Kristaps Atstupens; Maksims Mukans; Haralds Plaudis; Guntars Pupelis
Journal:  Medicina (Kaunas)       Date:  2020-05-20       Impact factor: 2.430

4.  Safe laparoscopic clearance of the common bile duct in emergently admitted patients with choledocholithiasis and cholangitis.

Authors:  Kristaps Atstupens; Haralds Plaudis; Vladimirs Fokins; Maksims Mukans; Guntars Pupelis
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2016-05-11

5.  Feasibility of gadoxetate disodium enhanced 3D T1 MR cholangiography (MRC) with a specific inversion recovery prepulse for the assessment of the hepatobiliary system.

Authors:  Ute Lina Fahlenkamp; Lisa Christine Adams; Sarah Maria Böker; Günther Engel; Minh Huynh Anh; Moritz Wagner; Bernd Hamm; Marcus Richard Makowski
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.